• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非酒精性脂肪性肝炎(NASH)导致肝癌的发病率令人震惊地增加。

Alarming increase of NASH as cause of liver cancer.

机构信息

Departamento de Gastrenterologia, Centro Hospitalar Lisboa Norte, Lisbon, Portugal.

Clínica Universitária de Gastrenterologia, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal.

出版信息

Cell Rep Med. 2022 Aug 16;3(8):100723. doi: 10.1016/j.xcrm.2022.100723.

DOI:10.1016/j.xcrm.2022.100723
PMID:35977465
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9418847/
Abstract

A very interesting recent article by Huang and colleagues evaluated the global epidemiology of liver cancer from 2010 to 2019 and showed that non-alcoholic steatohepatitis (NASH) is the fastest growing cause of hepatocellular carcinoma (HCC)..

摘要

一篇非常有趣的近期文章由 Huang 及其同事撰写,评估了 2010 年至 2019 年全球肝癌流行病学情况,并表明非酒精性脂肪性肝炎(NASH)是导致肝细胞癌(HCC)的增长最快的原因。

相似文献

1
Alarming increase of NASH as cause of liver cancer.非酒精性脂肪性肝炎(NASH)导致肝癌的发病率令人震惊地增加。
Cell Rep Med. 2022 Aug 16;3(8):100723. doi: 10.1016/j.xcrm.2022.100723.
2
Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.非酒精性脂肪性肝病相关肝细胞癌:日益受到关注。
Indian J Med Res. 2019 Jan;149(1):9-17. doi: 10.4103/ijmr.IJMR_1456_17.
3
Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma: A Growing Epidemic?非酒精性脂肪性肝炎相关肝细胞癌:一种日益流行的疾病?
Dig Dis. 2015 Sep;33(5):642-7. doi: 10.1159/000438473. Epub 2015 Sep 23.
4
Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma.非酒精性脂肪性肝病/非酒精性脂肪性肝炎与肝细胞癌。
Clin Liver Dis. 2018 Feb;22(1):201-211. doi: 10.1016/j.cld.2017.08.014.
5
Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases.系统评价与荟萃分析:非酒精性脂肪性肝炎且无肝硬化与其他肝病相比发生肝细胞癌的风险。
Aliment Pharmacol Ther. 2018 Oct;48(7):696-703. doi: 10.1111/apt.14937. Epub 2018 Aug 22.
6
Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates.非酒精性脂肪性肝炎是肝移植候选者中肝细胞癌增长最快的病因。
Clin Gastroenterol Hepatol. 2019 Mar;17(4):748-755.e3. doi: 10.1016/j.cgh.2018.05.057. Epub 2018 Jun 14.
7
Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience.非肝硬化非酒精性脂肪性肝病和代谢综合征背景下的肝细胞癌:美国的经验
Dig Dis Sci. 2015 Oct;60(10):3142-8. doi: 10.1007/s10620-015-3821-7. Epub 2015 Aug 7.
8
The epidemiology of non-alcoholic fatty liver disease.非酒精性脂肪性肝病的流行病学。
Liver Int. 2017 Jan;37 Suppl 1:81-84. doi: 10.1111/liv.13299.
9
Nonalcoholic fatty liver disease and hepatocellular carcinoma.非酒精性脂肪性肝病与肝细胞癌
Metabolism. 2016 Aug;65(8):1151-60. doi: 10.1016/j.metabol.2016.01.010. Epub 2016 Jan 23.
10
Bariatric surgery is associated with reduction in non-alcoholic steatohepatitis and hepatocellular carcinoma: A propensity matched analysis.减重手术与非酒精性脂肪性肝炎和肝细胞癌的减少有关:一项倾向评分匹配分析。
Am J Surg. 2020 Mar;219(3):504-507. doi: 10.1016/j.amjsurg.2019.09.006. Epub 2019 Sep 16.

引用本文的文献

1
Trends and future projections of liver cancer attributable to metabolic dysfunction-associated steatohepatitis in China from 1990 to 2050.1990年至2050年中国代谢功能障碍相关脂肪性肝炎所致肝癌的趋势及未来预测
Sci Rep. 2025 Jul 2;15(1):23255. doi: 10.1038/s41598-025-06617-2.
2
Ebastine-mediated destabilization of E3 ligase MKRN1 protects against metabolic dysfunction-associated steatohepatitis.依巴斯汀介导的E3连接酶MKRN1的去稳定作用可预防代谢功能障碍相关脂肪性肝炎。
Cell Mol Life Sci. 2025 Jan 31;82(1):66. doi: 10.1007/s00018-024-05535-2.

本文引用的文献

1
Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer.2010 年至 2019 年全球肝癌流行病学变化:NASH 是肝癌增长最快的病因。
Cell Metab. 2022 Jul 5;34(7):969-977.e2. doi: 10.1016/j.cmet.2022.05.003. Epub 2022 Jun 3.
2
Artificial intelligence for the prevention and clinical management of hepatocellular carcinoma.人工智能在肝细胞癌的预防和临床管理中的应用。
J Hepatol. 2022 Jun;76(6):1348-1361. doi: 10.1016/j.jhep.2022.01.014.
3
Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis.非酒精性脂肪性肝病相关肝细胞癌的临床特征、监测、治疗分配和结局:系统评价和荟萃分析。
Lancet Oncol. 2022 Apr;23(4):521-530. doi: 10.1016/S1470-2045(22)00078-X. Epub 2022 Mar 4.
4
The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?全球非酒精性脂肪性肝病政策审查与准备指数:各国是否准备好应对这一无声的公共卫生挑战?
J Hepatol. 2022 Apr;76(4):771-780. doi: 10.1016/j.jhep.2021.10.025. Epub 2021 Dec 9.
5
The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality.欧洲肝脏研究学会-《柳叶刀》肝脏委员会:保护下一代欧洲人免受肝脏疾病并发症和过早死亡的影响。
Lancet. 2022 Jan 1;399(10319):61-116. doi: 10.1016/S0140-6736(21)01701-3. Epub 2021 Dec 2.
6
Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma.非酒精性脂肪性肝病与肝细胞癌的流行病学
JHEP Rep. 2021 May 11;3(4):100305. doi: 10.1016/j.jhepr.2021.100305. eCollection 2021 Aug.
7
Perspectives on youth-onset nonalcoholic fatty liver disease.青少年非酒精性脂肪性肝病的观点
Endocrinol Diabetes Metab. 2020 Sep 17;3(4):e00184. doi: 10.1002/edm2.184. eCollection 2020 Oct.
8
Cardiovascular morbidity, diabetes and cancer risk among children and adolescents with severe obesity.严重肥胖儿童和青少年的心血管发病率、糖尿病和癌症风险。
Cardiovasc Diabetol. 2020 Jun 13;19(1):79. doi: 10.1186/s12933-020-01052-1.
9
Epidemiology and surveillance for hepatocellular carcinoma: New trends.肝癌的流行病学和监测:新趋势。
J Hepatol. 2020 Feb;72(2):250-261. doi: 10.1016/j.jhep.2019.08.025.
10
From NASH to HCC: current concepts and future challenges.从 NASH 到 HCC:当前概念和未来挑战。
Nat Rev Gastroenterol Hepatol. 2019 Jul;16(7):411-428. doi: 10.1038/s41575-019-0145-7.